<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34797487</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-1904</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>3-4</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology</Title><ISOAbbreviation>J Neuroimmune Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Cyclophosphamide: a Therapeutic Option for Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>423</StartPage><EndPage>424</EndPage><MedlinePgn>423-424</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11481-021-10032-5</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Xiong</LastName><ForeName>Anji</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4342-3738</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Nanchong Central Hospital, The Second Clinical Medical College, North Sichuan Medical College, Nanchong, China. xionganji@126.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inflammation and Immunology Key Laboratory of Nanchong City, Sichuan, China. xionganji@126.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Xiang</LastName><ForeName>Qilang</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0003-0539-7468</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Nanchong Central Hospital, The Second Clinical Medical College, North Sichuan Medical College, Nanchong, China. norman511724@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Cao</LastName><ForeName>Yuzi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Nanchong Central Hospital, The Second Clinical Medical College, North Sichuan Medical College, Nanchong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shuai</LastName><ForeName>Shiquan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Nanchong Central Hospital, The Second Clinical Medical College, North Sichuan Medical College, Nanchong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inflammation and Immunology Key Laboratory of Nanchong City, Sichuan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neuroimmune Pharmacol</MedlineTA><NlmUniqueID>101256586</NlmUniqueID><ISSNLinking>1557-1890</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>8N3DW7272P</RegistryNumber><NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003520" MajorTopicYN="N">Cyclophosphamide</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>19</Day><Hour>12</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34797487</ArticleId><ArticleId IdType="doi">10.1007/s11481-021-10032-5</ArticleId><ArticleId IdType="pii">10.1007/s11481-021-10032-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Beers DR, Appel SH (2019) Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies. Lancet Neurol 18:211&#x2013;220</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30394-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Hauser SL, Harrington H, Weiner HL (1986) Failure of immunosuppression with a ten- to 14-day course of high-dose intravenous cyclophosphamide to alter the progression of amyotrophic lateral sclerosis. Arch Neurol 43:383&#x2013;384</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1986.00520040063021</ArticleId></ArticleIdList></Reference><Reference><Citation>Gourie-Devi M, Nalini A, Subbakrishna DK (1997) Temporary amelioration of symptoms with intravenous cyclophosphamide in amyotrophic lateral sclerosis. J Neurol Sci 150:167&#x2013;172</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(97)00083-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, Shaw PJ, Simmons Z, van den Berg LH (2017) Amyotrophic lateral sclerosis. Nature Reviews Disease Primers 3</Citation></Reference><Reference><Citation>Jaiswal MK (2018) Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Med Res Rev 39:733&#x2013;748</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21528</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM (2016) How neuroinflammation contributes to neurodegeneration. Science 353:777&#x2013;783</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aag2590</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringel SP, Murphy JR, Alderson MK, Bryan W, England JD, Miller RG, Petajan JH, Smith SA, Roelofs RI, Ziter F (1993) The natural history of amyotrophic lateral sclerosis. Neurology 43:1316&#x2013;1322</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.43.7.1316</ArticleId></ArticleIdList></Reference><Reference><Citation>Roche JC, Rojas-Garcia R, Scott KM, Scotton W, Ellis CE, Burman R, Wijesekera L, Turner MR, Leigh PN, Shaw CE, Al-Chalabi A (2012) A proposed staging system for amyotrophic lateral sclerosis. Brain 135:847&#x2013;852</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr351</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SA, Miller RG, Murphy JR, Ringel SP (1994) Treatment of ALS with high dose pulse cyclophosphamide. J Neurol Sci 124(Suppl):84&#x2013;87</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(94)90188-0</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>